drugset / Trial / NCT03446261

Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

NCT03446261

Phase 4 Completed 140 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of rosuvastatin/ezetimibe combination therapy compared to rosuvastatin monotherapy in Korean patients with type 2 diabetes mellitus and hypercholesterolemia

Timeline

Start
2018-02-23
Primary completion
2019-03-05
Completion
2019-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Rosuvastatin Small molecule 10 mg